Abstract:Abstract 1570 Poster Board I-594 Acute myeloid leukemia with normal cytogenetics (CN-AML) represents approximately 40-50% of de novo AML cases and constitutes the single largest cytogenetic group of AML. CN-AML is composed of a heterogeneous group of AML considered to be more or less in the intermediate prognostic category. Stratified prognostic determinants are required to predict which patients in this heterogeneous category have an increased risk of relapse, resistance to therapy or long term disease outcomes. The CCAAT enhancer binding protein alpha (C/EBPA) is a key transcription factor involved in regulation of granulocytic differentiation and myelopoiesis. In the past few years, various studies have suggested that C/EBPA is negatively regulated in certain AML patients. Impairments in C/EBPA signaling such as gene mutation, transcriptional dysregulation, as well as epigenetic modification via promoter hypermethylation have been identified in CN-AML and these alterations may play an important role in pathogenesis and may predict prognosis in these patients. In the current study, we investigated C/EBPA gene mutations and promoter hypermethylation in a series of 53 patients with CN-AML. In addition, we also analyzed two other frequent mutations (FLT3/ITD and NPM1) in these patients and correlated them with C/EBPA gene alterations. Genomic DNA was isolated from diagnostic bone marrow and peripheral blood samples. The C/EBPA gene mutations were detected by PCR amplification followed by direct DNA sequencing while the promoter hypermethylation was characterized by methylation-specific PCR analysis. The FLT3/ITD mutation and NPM1 mutation were detected by using multiplex PCR followed by capillary electrophoresis. The study included 28 female patients and 25 male patients, all adults, with a median age of 49 years. 13/53 (24.5%) patients were FLT3/ITD+/NPM1-, 11/53 (20.8%) patients were FLT3/ITD+/NPM1+, 9/53 (17.0%) patients were FLT3/ITD-/NPM1+, and 20/53 (37.7%) patients were FLT3/ITD-/NPM1-. Four out of the 53 cases (7.5%) displayed C/EBPA mutations, whereas 49 (92.5%) cases had only C/EBPA wild-type alleles. Of the 4 positive cases, three patients had N-terminal mutations only, while one patient had mutations in both the N- and C-terminal region. Two of the 4 positive cases also harbored both FLT3/ITD and NPM1 mutation simultaneously, while the other two patients had neither FLT3/ITD nor NPM1 mutations. In addition, 7 (13.2%) of the 53 cases displayed C/EBPA promoter hypermethylation. Interestingly they were all in CN-AML cases without FLT3/ITD or NPM1 mutations. None of the 7 patients with C/EBPA promoter hypermethylation showed C/EBPA mutation. In conclusion, C/EBPA mutation and promoter hypermethylation can be detected at a relatively low frequency in de novo CN-AML patients, suggesting they may contribute to leukemogenesis. C/EBPA mutation appears to be frequently seen “high-risk” AML (FLT3/ITD+/NPM1+; FLT3/ITD+/NPM1- or FLT3/ITD-/NPM1-), while C/EBPA hypermethylation appears to be more common in AML with FLT3/ITD- /NPM1- and is not associated with C/EBPA mutation. The clear prognostic relationship of C/EBPA alteration and FLT3/ITD, NPM1 mutation needs to be further validated. Disclosures No relevant conflicts of interest to declare.

CEBPE expression is an independent prognostic factor for acute myeloid leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients

CD7 expression and its prognostic significance in acute myeloid leukemia patients with wild-type or mutant CEBPA

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

High Expression of EBP is an Adverse Prognostic Factor for De Novo Acute Myeloid Leukemia

Dysregulation of CCAAT/enhancer binding protein-alpha (CEBPA) expression in the bone marrow of acute myeloid leukemia patients

CEBPA Are Independent Good Prognostic Factors in Pediatric Acute Myeloid Leukemia.

C/Ebpa Gene Mutation and C/Ebpa Promoter Hypermethylation in Acute Myeloid Leukemia with Normal Cytogenetics.

Prognostic Nomogram for Acute Myeloid Leukemia Patients With Biallelic CEBPA Mutations

CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1

Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)

Favorable Prognosis of Biallelic CEBPA Gene Mutations in Acute Myeloid Leukemia Patients: a Meta-Analysis

The prognostic factors in acute myeloid leukaemia with double‐mutated CCAAT/enhancer‐binding protein alpha <scp> ( <i>CEBPA</i> dm </scp> )

Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model

A CD8+ T cell related immune score predicts survival and refines the risk assessment in acute myeloid leukemia

Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia

Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations

Tumor Microenvironmental Competitive Endogenous RNA Network and Immune Cells Act As Robust Prognostic Predictor of Acute Myeloid Leukemia